^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | alrizomadlin (APG-115) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers
Published date:
10/12/2022
Excerpt:
A phase 1 multicenter study was conducted to evaluate the safety and efficacy of APG-115 +/- carboplatin in TP53 wildtype (wt) SGC....95% (21/22) had stabilization of their previously progressive disease. A PR rate of 13% of pts on mono and 25% of patients on combo was observed. The median PFS on pts treated with mono was 11.4 mo....APG-115 monotherapy demonstrates promising antitumor activity among patients with TP53 wt SGC with an acceptable safety profile.
